Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 16/20 | 0.61 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.55 |
| ▸ | LCK | P06239 | 2/20 | 0.55 |
| ▸ | MAP4K3 | Q8IVH8 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | IL2 | P60568 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17552380 | 0.88 | MAP4K1 (0.48) | MAP4K1CHEK1LCKMAP4K3ACHE | |
| SCHEMBL28687884 | 0.87 | MAP4K1 (0.67) | MAP4K1CHEK1LCKMAP4K3ACHE | |
| SCHEMBL28675330 | 0.86 | MAP4K1 (0.60) | MAP4K1CHEK1LCKMAP4K3ACHE | |
| SCHEMBL30290509 | 0.86 | MAP4K1 (0.60) | MAP4K1CHEK1LCKMAP4K3ACHE | |
| SCHEMBL28667479 | 0.86 | MAP4K1 (0.57) | MAP4K1CHEK1LCKMAP4K3ACHE | |
| SCHEMBL28682310 | 0.85 | MAP4K1 (0.59) | MAP4K1CHEK1LCKMAP4K3ACHE | |
| SCHEMBL30290640 | 0.84 | MAP4K1 (0.71) | MAP4K1CHEK1LCKMAP4K3ACHE | |
| SCHEMBL28674874 | 0.84 | MAP4K1 (0.71) | MAP4K1CHEK1LCKMAP4K3ACHE | |
| SCHEMBL28684663 | 0.83 | MAP4K1 (0.57) | MAP4K1CHEK1LCKMAP4K3ACHE | |
| SCHEMBL28672942 | 0.82 | MAP4K1 (0.56) | MAP4K1CHEK1LCKMAP4K3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9669028-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-06-06 | — | — | US | claimed |
| US-8791112-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-07-29 | — | — | US | claimed |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2013-04-25 | — | — | US | claimed |
| US-9962382-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-05-08 | — | — | US | disclosed |
| US-9962382-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-05-08 | — | — | US | disclosed |
| US-9669028-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-9669028-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2017-06-06 | — | — | US | disclosed |
| US-20160074395-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2016-03-17 | — | — | US | disclosed |
| US-20160060261-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC | 2016-03-03 | — | — | US | disclosed |
| US-20160060261-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC | 2016-03-03 | — | — | US | disclosed |
| US-9187473-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-9187473-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140309211-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309211-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-10-16 | — | — | US | disclosed |
| US-8791112-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-07-29 | — | — | US | disclosed |
| US-8791112-B2 | Substituted 5-(pyrazin-2-yl)-1H-pyrazolo [3, 4-B] pyridine and pyrazolo [3, 4-B] pyridine derivatives as protein kinase inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012135631-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ARRIEN PHARMAEUTICALS LLC (US) | 2012-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060261-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K9, MAP3K19, MAP4K2 | MAP4K1 17/4885CHEK1 339/4885LCK 48/4885 |
| US-20160074395-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K9, MAP3K19, MAP4K2 | MAP4K1 17/4885CHEK1 339/4885LCK 48/4885 |
| US-20140309211-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K9, MAP3K19, MAP4K2 | MAP4K1 17/4885CHEK1 339/4885LCK 48/4885 |
| US-20130102586-A1 | SUBSTITUTED 5-(PYRAZIN-2-YL)-1H-PYRAZOLO [3, 4-B] PYRIDINE AND PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS | MAP3K9, MAP3K19, MAP4K2 | MAP4K1 17/4885CHEK1 339/4885LCK 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.